InMode Ltd vs Altria Group Inc — how do they compare? InMode Ltd trades at $14.07 (market cap $806.05M), while Altria Group Inc trades at $71.29 (market cap $115.85B). The key difference: Altria Group Inc is far larger — about 143.7× InMode Ltd's market cap, and Altria Group Inc pays a 6.4% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and Altria Group Inc for 154 Days on average.
| INMD | MO | |
|---|---|---|
Market Cap | $806.05M | $115.85B |
Volume | 511,446 | 6,934,962 |
Sector | Health | Consumer Staples |
52-Week High | $16.62 | $74.92 |
52-Week Low | $12.76 | $54.72 |
Typical Hold Time | 29 Days | 154 Days |
Enterprise Value | $309.39M | $138.06B |
Dividend Yield | — | 6.4% |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, showing minimal daily movement with a 0.14% gain. The stock faces bearish technical signals despite attractive valuation metrics including a P/E of 11.58 and EV/EBITDA of 4.43. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while the company faces shareholder activism from Steel Partners' $16.75 per share acquisition offer. Revenue guidance for 2026 remains stable at $365M-$375M.
The investment case balances strong profitability margins against technical weakness and activist pressure. With 45% analyst buy ratings and no sell recommendations, fundamental value appears intact, but near-term price action suggests caution. Key catalysts include Q3 2026 earnings and resolution of the acquisition proposal, while risks include execution challenges and macroeconomic headwinds affecting aesthetic medicine demand.
Altria Group (MO) trades at $71.43, up 4.2% today, showing strong momentum despite mixed earnings history with two misses and one beat in recent quarters. The stock maintains a 6.6% dividend yield with 60 consecutive annual increases, supported by robust cash flow generation. Technical indicators show a bullish trend with current price near resistance at $71, while fundamentals reveal stable revenue around $20B annually but declining profit margins from 55.1% in 2024 to 34.5% in 2025.
MO presents a high-yield opportunity with strong cash flows but faces significant headwinds including negative shareholder equity, regulatory pressures, and declining cigarette volumes. Analyst consensus remains positive with 62% buy ratings and $69.71 price target, though the stock trades slightly above this target. The company's transition to smoke-free products remains critical for long-term sustainability amid changing consumer preferences.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →